Synthon successfully completes bioequivalence studies for Bempedoic Acid and Bempedoic Acid + Ezetimibe in US.
read moreSynthon is proud to announce the completion of two successful bioequivalence (BE) studies for Bempedoic acid, a product we are developing for our…
read moreWe are thrilled to meet our business partners, industry colleagues and friends at DCAT Week in New York City from March 20-23, 2023.
read moreSynthon donates a financial gift and materials to Amalia Children's Hospital.
read moreSynthon is pleased to announce that it has entered into a partnership with Saudi-based SAJA, to commercialize several products in KSA and GCC region.
read moreYou will be able to find us at the the upcoming international pharma event from CPHI Worldwide 2022 in Frankfurt, Germany.
read moreOur colleague Liselijn Wisman is raising funds during de Nijmeegse Vierdaagse for the Oogfonds. Her son Wikke has the rare Leber's disease.
read moreThe Top Employer Institute certified Synthon Hispania as a reference company: one of the organizations with the best conditions for their employees…
read moreJohn McCullough has been appointed as Chief Commercial Officer.
read more17th of September 2021 marks a very special day in the history of Synthon. For 30 years we have been putting great science to work to bring affordable…
read more